In a welcome move, GSK ADR saw its Relative Strength Rating improve from 69 to 75 on Monday.
This unique rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains often have an RS Rating of at least 80 as they launch their biggest runs. See if GSK ADR can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
GSK ADR is trying to complete a consolidation with a 45.92 buy point. See if the stock can break out in heavy trade.
The company posted negative growth for both sales and earnings last quarter. The company is expected to release its next quarterly numbers on or around Apr. 30.
GSK ADR holds the No. 4 rank among its peers in the Medical-Diversified industry group. AstraZeneca ADR is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
